Meeting Coverage

Meeting Coverage

video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....
video

Jae Hong Park, MD: Improving Outcomes, Minimizing Toxicity With CAR T-Cell Therapy in B-Cell...

Dr. Park reviews two studies identifying characteristics that can improve durability of outcome, without increasing toxicity, in patients with B-cell acute lymphocytic leukemia.
video

Frederick Locke, MD: CAR T-Cell Therapy in Relapsed/Refractory NHL

Based on results of the ZUMA-1 trial, axicabtagene ciloleucel was submitted to the FDA earlier this year for patients with chemotherapy-refractory, aggressive non-Hodgkin lymphomas....
video

Mathias Rummel, MD, PhD: Bendamustine-Rituximab “StiL” Beats R-CHOP for Indolent Lymphomas

Ten-year results from the randomized, phase III StiL trial show that bendamustine plus rituximab leads to longer progression-free survival than R-CHOP in patients with...
video

Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

Adding ibrutinib to treatment with CAR T-cell therapy was feasible, led to deeper remissions, and reduced the severity of cytokine release syndrome in patients...
video

Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

Dr. Gerds discusses results from an ongoing trial of glasdegib, a novel hedgehog inhibitor, in patients with heavily pretreated myelofibrosis and significant disease burden.
video

Nicholas J. Short, MD: Inotuzumab Plus Lower-Intensity Chemotherapy Safe, Effective in Older Patients with...

Dr. Short shares results from a “proof-of-concept” study of the combination of inotuzumab ozogamicin and mini-hyper-CVD chemotherapy in older patients with newly diagnosed acute...
video

Jeff P. Sharman, MD: Ublituximab Plus Ibrutinib Improves Response Rate in High-Risk CLL

The novel anti-CD20 monoclonal antibody ublituximab (when added to ibrutinib) yielded superior response rates than ibrutinib alone in patients with high-risk chronic lymphocytic leukemia....
video

Ruben Mesa, MD: Momelotinib Non-Inferior to Ruxolitinib in Myelofibrosis

Dr. Mesa reviews data from the SIMPLIFY 1 trial, which compared the novel JAK1/2 inhibitor momelotinib with ruxolintinib in patients with JAK inhibitor–naïve MF,...
video

Richard Stone, MD: New FLT3 Inhibitor Crenolanib Shows Promise in FLT3-Mutated AML

The FLT3 inhibitor crenolanib, when added to standard induction chemotherapy, was associated with high rates of minimal residual disease negativity in patients with FLT3-mutated...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.